|

DNX-2401 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 2: 1

Top Sponsors

  • University of California, San Francisco1

Indications

  • Recurrent WHO Grade III Glioma1
  • Recurrent Diffuse Midline Glioma, H3 K27M-Mutant1
  • Recurrent Diffuse Intrinsic Pontine Glioma1
  • WHO Grade III Glioma1
  • Diffuse Midline Glioma, H3 K27M-Mutant1

Birmingham, Alabama1 trial

Combination Therapy for the Treatment of Diffuse Midline Gliomas

University of Alabama at Birmingham

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.